PTC Therapeutics, Inc. Gain (Loss) on Disposition of Other Assets
PTC Therapeutics, Inc. (PTCT) reported Gain (Loss) on Disposition of Other Assets of -$163.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Income Statement › Other Income
us-gaap:GainLossOnSaleOfOtherAssets · last filed 2026-02-19
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for the quarter ending 2025-12-31 was $0.00.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for the quarter ending 2024-12-31 was -$269.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for the quarter ending 2024-03-31 was -$544.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for the quarter ending 2023-12-31 was -$671.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for fiscal 2025 was -$163.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for fiscal 2024 was -$345.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for fiscal 2023 was -$806.00K.
- PTC Therapeutics, Inc. gain (loss) on disposition of other assets for fiscal 2022 was -$80.00K.
| Period end | Gain (Loss) on Disposition of Other Assets 3 month | Gain (Loss) on Disposition of Other Assets 6 month | Gain (Loss) on Disposition of Other Assets 9 month | Gain (Loss) on Disposition of Other Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$163.00K 10-K · filed 2026-02-19 | ||
| 2025-09-30 | -$163.00K 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | -$269.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$345.00K 10-K · filed 2026-02-19 | ||
| 2024-09-30 | -$76.00K 10-Q · filed 2025-11-04 | |||
| 2024-03-31 | -$544.00K 10-Q · filed 2025-05-06 | -$1.22M derived: sum of 2 quarters · filed 2026-02-19 | -$1.22M derived: sum of 3 quarters · filed 2026-02-19 | |
| 2023-12-31 | -$671.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | -$673.00K derived: sum of 2 quarters · filed 2026-02-19 | -$806.00K 10-K · filed 2026-02-19 | |
| 2023-09-30 | -$2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$135.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$133.00K 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | -$80.00K 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |